BHC
NYSEBausch Health Companies Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks490%
2025-11-022026-04-26
Mix2790d
- Insider13(48%)
- Other6(22%)
- SEC Filings5(19%)
- Earnings3(11%)
Latest news
25 items- SECBausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bausch Health Companies Inc. (0000885590) (Filer)
- PRBAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTSFirst Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment chargeGAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year periodAdjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32%Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST Q
- PRBausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online OrderingThe skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channelsLAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced Biafine® Skin Recovery Emulsion is now offered through convenient online ordering in the United States. The well-known French skincare formula is available through select online channels.First developed in France in 1971, Biafine® is a lightweight emulsion formula designed to support the skin's natural barrier function while helping to maintain skin hydration and comfort. For decades, the formula has been recognized by dermatol
- SECSEC Form DEFA14A filed by Bausch Health Companies Inc.DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)
- SECSEC Form DEF 14A filed by Bausch Health Companies Inc.DEF 14A - Bausch Health Companies Inc. (0000885590) (Filer)
- INSIDERSEC Form 4 filed by Leung Sandra4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERSEC Form 4 filed by Paulson John4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERSEC Form 4 filed by Wechsler Amy B4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- PRBausch Health to Announce First Quarter 2026 Results on April 29, 2026LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate: Wednesday, April 29, 2026Time: 5:00 p.m. U.S. EDTWebcast: http://ir.bauschhealth.com/events-and-
- PRBausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship ProgramBausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER Scholarship Program, with applications open through June 10, 2026. The program will award six exceptional students, impacted by dermatologic conditions with scholarships of up to $10,000 each to support their pursuit of higher education. "It is an honor to continue the AS
- INSIDEREVP, CFO Charhon Jean-Jacques covered exercise/tax liability with 49,060 shares, decreasing direct ownership by 6% to 706,478 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDEREVP, General Counsel Carson Seana covered exercise/tax liability with 43,299 shares, sold $65,131 worth of shares (11,276 units at $5.78) and disposed of $820,636 worth of shares (137,922 units at $5.95), decreasing direct ownership by 24% to 616,761 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERChief Executive Officer Appio Thomas covered exercise/tax liability with 166,798 shares and disposed of $6,770,279 worth of shares (1,137,862 units at $5.95), decreasing direct ownership by 36% to 2,315,374 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- SECBausch Health Companies Inc. filed SEC Form 8-K: Leadership Update8-K - Bausch Health Companies Inc. (0000885590) (Filer)
- INSIDERSVP, Controller & CAO Lee Steven Hyosig was granted 45,868 shares, increasing direct ownership by 168% to 73,239 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDEREVP, US Pharma Lenar Aimee J. was granted 157,139 shares and covered exercise/tax liability with 17,578 shares, increasing direct ownership by 54% to 400,335 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDEREVP, General Counsel Carson Seana was granted 212,350 shares, covered exercise/tax liability with 32,211 shares and sold $49,909 worth of shares (8,388 units at $5.95), increasing direct ownership by 27% to 809,258 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDEREVP, CFO Charhon Jean-Jacques was granted 276,055 shares and covered exercise/tax liability with 35,977 shares, increasing direct ownership by 47% to 755,538 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERChief Executive Officer Appio Thomas was granted 815,425 shares and covered exercise/tax liability with 116,502 shares, increasing direct ownership by 24% to 3,620,034 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- PRBausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in CanadaLAVAL, QC, Feb. 23, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada. With this approval, Canadian physicians are able to offer one of the most advanced dual-wavelength laser technologies on the market, expanding access to customizable treatments that align with the country's growing preference for effective yet approachable s
- PRBausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) MicrospheresThe only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical useLAVAL, QC, Feb. 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis. ARESTIN is supported by over two decades of clinical experience and remains the only Food and Drug Administration (FDA) approved locally applied antibiotic for this use.Dan Wu, Ph
- SECBausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bausch Health Companies Inc. (0000885590) (Filer)
- PRBAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTSFourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y
- PRBausch Health to Participate in the J.P. Morgan Global Leveraged Finance ConferenceLAVAL, QC, Feb. 17, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Executive Vice President and CFO Jean-Jacques (JJ) Charhon, along with other management team members, will attend the J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida, from March 2–4, 2026, to meet with investors.About Bausch HealthBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, internation
- INSIDERChief Executive Officer Appio Thomas was granted 1,137,862 shares, increasing direct ownership by 64% to 2,921,111 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
BHC FAQ
6 questionsWhat does Bausch Health Companies Inc. do?
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products...Where does BHC stock trade?
Bausch Health Companies Inc. (BHC) is listed on NYSE.What sector and industry is BHC in?
Bausch Health Companies Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BHC?
Bausch Health Companies Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $800.00 price target on 2025-12-09.What companies are similar to BHC?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare BHC side-by-side with any of them on Quantisnow.How can I track BHC on Quantisnow?
Quantisnow aggregates Bausch Health Companies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BHC to receive live email and push alerts on every new disclosure.